Skip to main content

Relexxii Dosage

Medically reviewed by Last updated on Nov 24, 2021.

Dosage form: tablet, extended release

General Dosing Information

RELEXXII® should be administered orally once daily in the morning with or without food.

RELEXXII® must be swallowed whole with the aid of liquids, and must not be chewed, divided, or crushed [see Patient Counseling Information (17)].

Patients New to Methylphenidate

The recommended starting dose of methylphenidate hydrochloride extended-release tablets for patients who are not currently taking methylphenidate or stimulants other than methylphenidate is 18 mg once daily for adolescents and 18 or 36 mg once daily for adults (see Table 1).

Table 1. Methylphenidate Hydrochloride Extended-release Tablets Recommended Starting Doses and Dose Ranges

Patient Age

Recommended Starting Dose

Dose Range

Children 6–12 years of age

18 mg/day

18 mg – 54 mg/day

Adolescents 13–17 years of age

18 mg/day

18 mg – 72 mg/day
not to exceed 2 mg/kg/day

Adults 18–65 years of age

18 or 36 mg/day

18 mg – 72 mg/day

Patients Currently Using Methylphenidate

The recommended dose of methylphenidate hydrochloride extended-release tablets for patients who are currently taking methylphenidate twice daily or three times daily at doses of 10 to 60 mg/day is provided in Table 2. Dosing recommendations are based on current dose regimen and clinical judgment. Conversion dosage should not exceed 72 mg daily.

Table 2. Recommended Dose Conversion from Methylphenidate Regimens to Methylphenidate Hydrochloride Extended-release Tablets

Previous Methylphenidate Daily Dose

Recommended Methylphenidate Hydrochloride Extended-release Tablets Starting Dose

5 mg Methylphenidate twice daily or three times daily

18 mg every morning

10 mg Methylphenidate twice daily or three times daily

36 mg every morning

15 mg Methylphenidate twice daily or three times daily

54 mg every morning

20 mg Methylphenidate twice daily or three times daily

72 mg every morning

Other methylphenidate regimens: Clinical judgment should be used when selecting the starting dose.

Dose Titration

Doses may be increased in 18 mg increments at weekly intervals for patients who have not achieved an optimal response at a lower dose. Daily dosages above 54 mg in children and 72 mg in adolescents have not been studied and are not recommended. Daily dosages above 72 mg in adults are not recommended.

A 27 mg dosage strength is available for physicians who wish to prescribe between the 18 mg and 36 mg dosages.

Maintenance/Extended Treatment

There is no body of evidence available from controlled trials to indicate how long the patient with ADHD should be treated with RELEXXII®. It is generally agreed, however, that pharmacological treatment of ADHD may be needed for extended periods.

The effectiveness of RELEXXII® for long-term use, i.e., for more than 7 weeks, has not been systematically evaluated in controlled trials. The physician who elects to use RELEXXII® for extended periods in patients with ADHD should periodically re-evaluate the long-term usefulness of the drug for the individual patient with trials off medication to assess the patient's functioning without pharmacotherapy. Improvement may be sustained when the drug is either temporarily or permanently discontinued.

Dose Reduction and Discontinuation

If paradoxical aggravation of symptoms or other adverse events occur, the dosage should be reduced, or, if necessary, the drug should be discontinued.

If improvement is not observed after appropriate dosage adjustment over a one-month period, the drug should be discontinued.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.